0001387131-20-008322.txt : 20200915 0001387131-20-008322.hdr.sgml : 20200915 20200915162137 ACCESSION NUMBER: 0001387131-20-008322 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20200914 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200915 DATE AS OF CHANGE: 20200915 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Adamis Pharmaceuticals Corp CENTRAL INDEX KEY: 0000887247 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 820429727 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36242 FILM NUMBER: 201176223 BUSINESS ADDRESS: STREET 1: 11682 EL CAMINO REAL STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 997-2400 MAIL ADDRESS: STREET 1: 11682 EL CAMINO REAL STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: CELLEGY PHARMACEUTICALS INC DATE OF NAME CHANGE: 19950615 8-K 1 admp-8k_091420.htm CURRENT REPORT
0000887247 false 0000887247 2020-09-14 2020-09-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 14, 2020

 

ADAMIS PHARMACEUTICALS CORPORATION

 

(Exact Name of Registrant as Specified in Charter)

 

Delaware   0-26372   82-0429727

(State or other jurisdiction

of incorporation)

   (Commission File Number)  

(IRS Employer

Identification No.)

         

11682 El Camino Real, Suite 300

San Diego, CA

      

 

92130

(Address of Principal Executive Offices)       (Zip Code)

 

Registrant’s telephone number, including area code: (858) 997-2400

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company            ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock ADMP NASDAQ Capital Market

 

 
 
Item 1.01Entry Into a Material Definitive Agreement.

 

On September 14, 2020, Adamis Pharmaceuticals Corporation (the “Company”) entered into an amendment (the “Amendment”) to its loan amendment and assumption agreement with Arvest Bank, as successor in interest to Bear State Bank, N.A. (“Lender” or the “Bank”), and a related amended and restated promissory note (the “Note”). The Amendment amends the Business Loan Agreement (as modified, amended or supplemented, the “Loan Agreement”), promissory note and related loan documents (as modified, amended or supplemented, the “Loan Documents”) that the Company assumed or entered into in connection with its acquisition of U.S. Compounding, Inc. in 2016. The Amendment memorializes and reflects the extension of the maturity date of the indebtedness evidenced by the Loan Agreement, the Note and the Loan Documents to August 8, 2021. The Note bears interest at a rate equal to the lesser of: (a) the maximum rate of interest which the Bank may lawfully charge under applicable law, or (b) a rate equal to the sum of the prime commercial rate of interest as reflected in the Wall Street Journal charged by banks in New York, New York on August 1, 2020, as adjusted daily, plus 2.5%, provided, however, that the interest rate at any time during the term of the Note will not be less than 6.0% per annum. The Company will make monthly payments of principal and interest based on a 168-month amortization period, with the remaining outstanding principal balance and any accrued unpaid interest and any other sums payable under the Note or Loan Documents due on the maturity date described above. The Note provides for a late charge fee with respect to any installment payment not received by the Bank within 10 days after the due date of the installment. The Note is subject to customary event of default and acceleration provisions permitting Lender to declare all outstanding indebtedness due and payable, including without limitation following failure to pay amounts due, bankruptcy filings or similar insolvency or reorganization proceedings, and defaults by the Company under the terms of the security agreement, mortgage, guaranties or similar agreements or documents relating to the Note. The other terms of the Loan Agreement were not amended in any material respect.

Item 2.03Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information set forth in Item 1.01 is incorporated by reference into this Item.

Item 9.01Financial Statements and Exhibits

 

Exhibit No.   Description
10.1   August 2020 Amendment to Loan Amendment and Assumption Agreement between the Company and Arvest Bank.
10.2   Amended Promissory Note between the Company and Arvest Bank.

 

 

 
 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  ADAMIS PHARMACEUTICALS CORPORATION
     
     
     
Dated:  September 15, 2020 By: /s/ Robert O. Hopkins
    Name:  Robert O. Hopkins
    Title:  Chief Financial Officer

 

 

 

 

 

 EX-10.1 2 ex10-1.htm AUGUST 2020 AMENDMENT TO LOAN AMENDMENT AND ASSUMPTION AGREEMENT

 

Adamis Pharmaceuticals Corporation 8-K

 

Exhibit 10.1

 

AUGUST 2020 AMENDMENT TO LOAN AMENDMENT
AND ASSUMPTION AGREEMENT
Loan No. 5500000152

THIS AUGUST 2020 AMENDMENT TO LOAN AMENDMENT AND ASSUMPTION AGREEMENT (the “August 2020 Amendment”) is entered into this 8th day of August, 2020, by and among US COMPOUNDING, INC., an Arkansas corporation (“USC”), ADAMIS PHARMACEUTICALS CORPORATION, a Delaware corporation (“Adamis” and together with USC, the “Borrower”), and ARVEST BANK, an Arkansas state bank, as successor in interest to BEAR STATE BANK, N.A. (“Lender”).

BACKGROUND

A.                 Pursuant to that certain Business Loan Agreement (as modified, amended or supplemented, the “Loan Agreement”) dated as of August 8, 2014, entered into by and between 4 HIMS, as borrower, and Bank, as lender, Bank agreed to make a loan, Loan No. 5500000152 (the “Loan”) to 4 HIMS, LLC, an Arkansas limited liability company (“4 HIMS”) (4 HIMS and USC are collectively hereinafter referred to as the “Initial Loan Parties”), in the initial principal amount of up to Two Million Five Hundred Eighty-Six Thousand Eight Hundred Ninety-Two and 09/100 Dollars ($2,586,892.09), The Loan is evidenced by that certain September 2016 Amended, Restated and Substituted Promissory Note (the “Note”) dated effective as of September 30, 2016, executed by USC, 4 HIMS and Adamis in favor of Lender, which is a substitution and replacement of that certain Commercial Promissory Note (as modified, amended or supplemented, the “Initial Note”) dated as of August 8, 2014, executed by 4 HIMS in favor of Lender. The Note is secured by, among other things, that certain Commercial Real Estate Mortgage (as modified, amended or supplemented, the “Mortgage”) dated as of August 8, 2014, executed by 4 HIMS in favor of Lender and recorded in the Official Records of Faulkner County as Document #2014 11418, encumbering certain real property more particularly described in the Mortgage. In connection with the Loan, 4 HIMS also entered into certain other agreements and instruments, (the Loan Agreement, the Note, the Mortgage and all other documents executed in connection with the Loan, all as previously modified, amended or supplemented, collectively referred herein as the “Loan Documents”). EDDIE GLOVER, an individual, and WILLIAM L. SPARKS, an individual; and KRISTEN RIDDLE, an individual (collectively, the “Individual Guarantors”) and USC guaranteed repayment of the Loan pursuant to those certain documents each titled Guaranty of Specific Transaction (such guarantees by the Individual Guarantors and USC, as may be modified, amended or supplemented, referred to as the “Guarantees”) dated as of August 8, 2014, entered into by each such Guarantor for the benefit of Lender.

B.                 Adamis entered into a merger transaction with USC (the “Merger”), pursuant to that certain Agreement and Plan of Merger dated as of March 28, 2016 (the “Merger Agreement”), USC’s principal offices are currently located on the Property. In connection with the Merger, Adamis acquired from 4 HIMS the entire fee simple interest in and to the real property and tangible assets that 4 HIMS has agreed to sell and transfer to Adamis (the “Property”) pursuant to that certain Purchase and Sale Agreement dated as of March 28, 2016, and entered into by and between Adamis and 4 HIMS for consideration consisting only of the assumption of the Loan by Adamis.

C.                 In April 2016, the parties hereto entered into that certain Loan Amendment, Forbearance and Assumption Agreement whereby the Individual Guarantors were released.

D.                 In September 2016, the parties hereto entered into that certain Loan Amendment and Assumption Agreement whereby Adamis was added as a co-borrower to the Loan Documents.

E.                 Borrower and Lender desire the Loan Agreement be further amended as set forth in this August 2020 Amendment, but that all other terms, conditions, and provisions of the Loan Agreement remain in full force and effect solely except as set forth in this August 2020 Amendment.

F.                  Borrower hereby intends to and by execution hereof ratifies and affirms Borrower’s unqualified and unconditional liability on all indebtedness of the Loan.

NOW, THEREFORE, for and in consideration of Lender’s agreement to the amendments set forth in this August 2020 Amendment, the Loan Agreement, and the covenants, warranties and representations of Borrower contained herein, Ten Dollars ($10.00) and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by all parties, it is agreed as follows:

 1 
 

 

AGREEMENTS

The recitals set forth above are not mere recitals of fact but are contractual in nature and are intended by the parties to be incorporated into this August 2020 Amendment by reference, except in the event of a conflict between the incorporated recitals and the numbered sections of this August 2020 Amendment, the numbered sections of this August 2020 Amendment shall control. Terms and provisions which are not otherwise defined herein shall have the same meanings as set forth in the Loan Agreement.

1.       Extension of Maturity of Loan. Borrower and Lender agree the Maturity Date of foe indebtedness evidenced by the Loan Agreement and the other documents evidencing and securing the Loan, shall be August 8, 2021, as fully set forth in that certain August 2020 Amended and Restated Promissory Note executed of even date herewith (the “August 2020 Note”).

2.       Tax Escrow. Borrower and Lender agree Borrower shall deposit with Lender each month during the term of this Loan, on the date each monthly payment is due pursuant to the August 2020 Note, 1/12th of the estimated annual ad valorem tax liability of Borrower, which sums Lender shall use to pay ad valorem taxes directly to the taxing authority.

3.        Estoppel; Waiver; Ratification and Release. For and in consideration of the maturity extension granted by Lender herein, Ten United States Dollars ($10.00) and other good and valuable consideration, receipt and sufficiency being acknowledged, Borrower, as evidenced by its signature below, agrees and acknowledges its unqualified and unconditional obligation for the Indebtedness without defense, affirmative defense, counterclaim, right of setoff or other impediment to collection, and tire same, if existing, being expressly released and waived by Borrower in consideration for Lender entering into this August 2020 Amendment.

4.       UCC. Notwithstanding any provisions hereof or execution by Lender, this August 2020 Amendment (and all documents executed in connection herewith) shall be voidable at the option of Lender should any lien searches or other confirmatory title information regarding the Collateral (to be provided at the expense of Borrower) reflect any default under the Loan or creation of any adverse claim or interest regarding the Collateral. In addition, Borrower authorizes Lender to file any and all initial, amendatory or continuation Uniform Commercial Code filings deemed necessary by Lender.

5.       Good Standing of Borrower. Notwithstanding any provisions hereof or execution by Lender, this August 2020 Amendment (and all documents executed in connection herewith) shall be voidable at the option of Lender in the event Borrower is not validly existing and under its state of formation at the time of execution of this August 2020 Amendment.

6.        No Further Modifications. Except as expressly set forth above, the terms and provisions of the Loan Agreement shall remain in full force and effect.

[Signatures appear on following page.]

 2 
 

 

IN WITNESS WHEREOF, the parties hereto have duly executed this August 2020 Amendment this _____ day of August, 2020.

 

 

  BORROWER:
   
  ADAMIS PHARMACEUTICALS CORPORATION,
  a Delaware corporation
   
   
   
  By: /s/ Robert O. Hopkins
  Name: Robert O. Hopkins
  Title: SVP & CFO
   
   
  US COMPOUNDING, INC.,
  an Arkansas corporation
   
   
   
  By: /s/ Robert O. Hopkins
  Name: Robert O. Hopkins
  Title: SVP & CFO
   
   
  LENDER:
   
  ARVEST BANK,
  an Arkansas state bank
   
   
   
  By: /s/ Tony Bornhoft
  Name: Tony Bornhoft
  Title: Director Special Assets

 

 

 

 

 3 

 EX-10.2 3 ex10-2.htm AMENDED PROMISSORY NOTE
 

Adamis Pharmaceuticals Corporation 8-K

 

Exhibit 10.2

 

AUGUST 2020 AMENDED AND RESTATED
PROMISSORY NOTE
Loan No. 5500000152

$2,092,112.00 August 8, 2020
  Little Rock, Arkansas

FOR VALUE RECEIVED, US COMPOUNDING, INC., an Arkansas corporation (“USC”), and ADAMIS PHARMACEUTICALS CORPORATION, a Delaware corporation (“Adamis” and together with USC, the “Maker”), jointly, severally, unconditionally and irrevocably promise to pay to the order of ARVEST BANK, an Arkansas state bank, as successor in interest to BEAR STATE BANK, N.A., whose mailing address is 2200 W. Pleasant Grove Road, Rogers, Arkansas 72758, its successors and assigns (“Bank”), or to the order of any subsequent holder hereof, in lawful money of the United States of America, the principal sum of Two Million Ninety Two Thousand One Hundred Twelve and No/100 United States Dollars ($2,092,112.00), or so much as may be advanced hereunder, together with interest on the unpaid principal balance (calculated on the basis of a hypothetical year of three hundred sixty (360) days, but multiplied by the actual number of days in the interest calculation period), from the date hereof at a variable rate which shall, from day to day, be equal to the lesser of: (a) the maximum rate of interest which Bank may lawfully charge under applicable Law in effect from time to time (the “Maximum Rate”), or (b) a rate equal to the sum of: (i) the prime commercial rate of interest charged by banks in New York, New York, as reflected in the Central Edition of The Wall Street Journal (the “Prime Rate”) as posted on August 1, 2020, plus (ii) two and one half of one percent (2.50%), provided however, the interest rate at any time during the term of this August 2020 Note shall not be less than six percent (6.00%) per annum. The interest rate shall be adjusted, daily. Maker further agrees changes in the Prime Rate shall automatically result in a change in the interest charged pursuant to this August 2020 Amended and Restated Promissory Note (the “August 2020 Note”), and such change in the interest rate shall be effective regardless of notice to Maker, resulting in recomputation of the required monthly payment of principal and interest.

In the event the foregoing provisions should be construed by a court of competent jurisdiction not to constitute a valid, enforceable designation of a rate of interest or method of determining same, the unpaid principal balance pursuant to this August 2020 Note shall bear interest at the Maximum Rate. Repayment of the indebtedness represented hereby shall be as follows:

Commencing on September 8, 2020, Maker shall pay to Bank monthly payments of principal and interest, based on a one hundred sixty eight (168) month amortization period, with a final payment of the entire outstanding principal balance, all accrued and unpaid interest, accrued as of the Maturity Date, and all other sums payable pursuant to this August 2020 Note, or any of the other Security Documents (defined below) being absolutely and unconditionally due and payable on August 8, 2021 (the “Maturity Date”), unless sooner provided.

Bank undertakes no obligation to extend the maturity of this August 2020 Note, and Maker acknowledges and agrees that no such representation has been made to Maker by Bank, or anyone by or on behalf of Bank.

All installments of principal and interest shall be payable to Bank at P.O. Box 1219, Lowell, Arkansas 72745, or such other places as Bank or the holder hereof may designate in writing from time to time. If any payment of principal and interest on this August 2020 Note shall become due on a Saturday, Sunday or public holiday under the laws of the State of Arkansas, on which the Bank or subsequent holder is not open for business, such payment shall be made on the next succeeding business day and such extension of time shall in such case be included in computing interest in connection with such payment.

There shall be due from Maker to Bank, in addition to all other amounts set forth herein, the sum of Five Hundred and No/100 United States Dollars ($500.00) plus any legal fees as a loan origination fee payable on or before the execution date of this Note. This fee is fully earned when paid, non-refundable and shall not apply as a payment toward principal or interest.

 - 1 - 
 

 

Maker shall pay to Bank a late charge for any installment not received by the Bank within ten (10) days after the installment is due in the amount of four percent (4.0%) of the applicable installment and notwithstanding the above; such late charge shall apply separately to each installment past due, but shall only be assessed once as to each late payment. Maker stipulates and agrees that any such late charge(s) shall not be deemed to be additional interest but shall compensate for Bank’s administrative expenses of addressing late payments. This provision for late charges shall not be deemed to extend the time for payment or be a “grace period” or “cure period” that gives Maker a right to cure a default. Imposition of late charges is not contingent upon the giving of any notice or lapse of any cure period provided for in the Mortgage and shall not be deemed a waiver of any right or remedy of Bank, including without limitation, acceleration of this August 2020 Note.

This August 2020 Note may be prepaid in whole or in part. All payments and prepayments made by Maker are to be applied first to any late charges, protective disbursements, and other reimbursements owed to Bank; then in the reduction of interest then due at the rate stated herein; and any amount remaining after such payment of interest shall be applied in reduction of the outstanding principal balance due hereunder.

Upon the occurrence of any of the following events of default (an “Event of Default”), the holder hereof may declare the entire outstanding indebtedness of Maker evidenced by this August 2020 Note due and payable as to principal and accrued interest including any late charges:

(a)                  Maker shall fail to pay any amount of principal or interest or any pail thereof, under this August 2020 Note by the due date thereof; or

(b)                 Maker shall Voluntarily become a party to any insolvency, bankruptcy, composition or reorganization proceeding; or make any assignment for the benefit of creditors; or if any involuntary bankruptcy, insolvency, composition, or other reorganization proceeding be filed against Maker, and the same shall not be dismissed within thirty (30) days alter the commencement of any such involuntary proceeding; or

(c)                Upon any default in any of the terms, warranties, covenants, provisions obligations contained in any Security Document (defined herein) or under any other promissory note or guaranty executed by or other obligation owed (directly or as a guarantor of indebtedness owed to Bank by any person or entity) by Maker to Bank; or

(d)                Upon any default in any other trust deed, mortgage, security agreement, assignment, or other instrument of pledge, security or hypothecation which now or hereafter secures the payment of the indebtedness evidenced hereby; or

(e)                Upon any default by Maker in any of the terms, warranties, covenants, provisions or obligations contained in the Warrant (as defined in the Security Documents); or

(f)                 Upon any default in any of the terms, warranties, covenants ox provisions of any of the Security Documents (defined below) or any other promissory note executed by or other obligation owed by Maker to Bank entitling Bank to accelerate the maturity of this August 2020 Note.

If this August 2020 Note is placed in the hands of an attorney for collection, by suit or otherwise, or for the protection of Bank’s interest hereunder, Maker shall pay all costs of collection and all court costs and attorneys’ fees, costs and expenses incurred by Bank, including, but not limited to, attorneys’ fees, costs and expenses incurred in any bankruptcy proceeding in which Maker or any other obligor appears as a debtor.

From and after the Maturity Date hereof or the date of default (in the event of acceleration of the indebtedness evidenced hereby by reason of Maker’s default or otherwise), the entire indebtedness due hereunder including any accrued interest and late charges shall bear interest, at the option of Bank, at a rate equal to the lesser of (i) the rate in effect at the time of default, plus three percent (3.0%); or (ii) the Maximum Rate, until payment in full of all principal and interest, late payment charges and other sums due hereunder are made.

Maker waives presentment, demand, protest, and notice of protest, demand, dishonor and nonpayment.

 - 2 - 
 

Time is of the essence of all obligations to be performed by Maker hereunder. Any reference herein or in the other Security Documents to a day or business day shall be deemed to refer to a banking day which shall be a day on which Bank is open for the transaction of business, excluding any national holidays, and any performance which would otherwise be required on a day other than a banking day shall be timely performed in such instance, if performed on the next succeeding business day. Notwithstanding such timely performance, ‘interest shall continue to accrue hereunder until such payment or performance has been made.

Maker authorizes Bank, as provided in the Security Documents, without notice or demand and without affecting its liability hereunder, from time to time, to take and hold security for the payment of this August 2020 Note or any renewals or extensions hereof; perfect such security, whether or not such security is required as a condition to the making of the Loan evidenced by this August 2020 Note; exchange, enforce, waive or release (whether intentionally or unintentionally) any such security, or any part thereof; purchase such security at a public or private sale (without any obligation to so purchase) and apply such security and direct the order or manner of sale thereof as Bank, in its discretion, may determine.

It is the intention of Bank and Maker to comply strictly with applicable usury law, as may be preempted by federal law. In no event, and upon no contingency, shall die Bank or subsequent holder hereof ever be entitled to receive, collect or apply as interest, any interest, fees, charges or other payments equivalent to interest, in excess of the Maximum Rate which Bank may lawfully charge under applicable statutes and laws from time to time in effect; and in the event the Bank or subsequent holder hereof ever receives, collects, or applies as interest, any such excess, which, but for this provision, would be excessive interest, shall be applied to the reduction of the principal amount of the indebtedness hereby evidenced; and if the principal amount of the indebtedness evidenced hereby, all lawful interest thereon and all lawful fees, prepayment premiums and charges in connection therewith, are paid in full, any remaining excess shall forthwith be paid to Maker, or other party lawfully entitled thereto. Any provision hereof or any other agreement between the Bank and Maker that operates to bind, obligate or compel the undersigned to pay interest in excess of the Maximum Rate shall be construed to require the payment of the Maximum Rate only. The provisions of this paragraph shall be given precedence over any other provision contained herein, or in any other agreement between the holder and the undersigned that it is in conflict with the provisions of this paragraph.

If any provision hereof shall be construed to be invalid or unenforceable, the remaining provisions hereof shall not be affected by such invalidity or unenforceability. Each term or provision hereof shall, however, be valid and be enforced to the fullest extent permitted by law.

This August 2020 Note and the indebtedness represented and evidenced hereby is secured by, among other things, a Loan Amendment and Assumption Agreement executed September 30, 2016 (as subsequently amended), and, upon mutual agreement of Maker and Bank, may now or hereafter be secured by other mortgages, guaranties, trust deeds, assignments, security agreements, or other instruments of pledge or hypothecation (collectively, the “Security Documents” or separately, a “Security Document”).

Upon the occurrence of any Event of Default, Bank shall have the right, immediately, and without notice to the Maker, to set off against this August 2020 Note all money owed by the Bank in any capacity to Maker, or to any endorser or other person who is or may be liable for payment hereof, whether or not due, and the Bank shall be deemed to have exercised such right of setoff and to have made a charge against such money immediately upon the occurrence of such Event of Default even though such charge is made or entered on the books of the Bank subsequently thereto.

The rights, obligations and liabilities of Maker hereunder may not be assigned, either in whole or in part, to any other person or party whomsoever. This August 2020 Note may be negotiated or assigned by Bank, either in whole or in part, and any negotiation or assignment hereof or of the Security Documents, or any portion or portions hereof or thereof, shall operate to vest in any such transferee the rights and powers, either in whole or in part, as the context so requires, herein and therein granted to Bank. In the event Bank shall transfer this August 2020 Note or the other Security Documents in whole, Bank shall thereupon be relieved of all duties, responsibilities and liabilities whatsoever hereunder or thereunder. Bank may share with any potential transferee or participant any information regarding Maker or any collateral securing this August 2020 Note.

 - 3 - 
 

This August 2020 Note shall be governed by and construed in accordance with the laws of tile State of Arkansas and, as to the maximum rate of interest, by applicable federal laws.

This August 2020 Note: (i) is merely an amendment and restatement of the existing debt obligations represented by that certain Promissory Note of 4 HIMS, LLC, an Arkansas limited liability company, in favor of Bank in the amount of $2,586,892.09 (Loan No. 5500000152) (the “Initial Note”) as amended by that certain September 2016 Amended, Restated and Substituted Promissory Note dated September 30, 2016 in the principal amount of $2,453,879.12 (the “September 2016 Note”); (ii) is not a novation, substitution or creation of a new debt obligation of Bank; and (iii) shall not change or affect in any manlier the conditions and stipulations of the documents evidencing or securing the loan evidenced by the Initial Note (collectively, the “Loan Documents”), except as herein specifically provided. Specifically, this Note merely restates, amends and substitutes the Initial Note and the September 2016 Note, the indebtedness hereinafter being evidenced by this Note without release of any other instrument, Security Document or Loan Document.

(Signature Page Follows.)

 - 4 - 
 

 

Signature Page
AUGUST 2020 AMENDED AND RESTATED PROMISSORY NOTE

MAKER AND BANK FULLY, VOLUNTARILY, KNOWINGLY, IRREVOCABLY AND UNCONDITIONALLY WAIVE ANY RIGHT TO A TRIAL BY JURY OR TO HAVE A JURY PARTICIPATE IN ANY DISPUTE, ACTION OR PROCEEDING TO ENFORCE OR DEFEND ANY RIGHTS (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) UNDER THIS AGREEMENT, OR UNDER ANY AMENDMENT, INSTRUMENT, DOCUMENT OR AGREEMENT DELIVERED (OR WHICH MAY IN THE FUTURE BE DELIVERED) IN CONNECTION HEREWITH. MAKER AND BANK AGREE THAT ANY SUCH ACTION OR PROCEEDING SHALL BE TRIED BEFORE A COURT AND NOT BEFORE A JURY. THIS PROVISION IS A MATERIAL INDUCEMENT TO BANK TO PROVIDE THE FINANCING TO MAKER PURSUANT HERETO. MAKER AND BANK ARE AWARE OF THE DECISIONS IN TILLEY V. MALVERN NATIONAL BANK, 2017 ARK. 343 (2017) AND 2019 ARK. 376 (2019), AND INTEND TO FOLLOW THE PROVISION OF ARK. CODE ANN. § 16-30-104; HOWEVER, TO THE EXTENT THE JURY TRIAL WAIVER PROVIDED HEREIN IS DEEMED UNENFORCEABLE, MAKER AND BANK AGREE SUCH PROVISION SHALL BE SEVERED WITHOUT AFFECT UPON THE ENFORCEABILITY OF THE REMAINING PROVISIONS OF THIS AUGUST 2020 NOTE.

  MAKER:
  US COMPOUNDING, INC.,
  an Arkansas corporation
   
   
   
  By: /s/ Robert O. Hopkins
  Name: Robert O. Hopkins
  Title: SVP & CFO
   
   
  ADAMIS PHARMACEUTICALS CORPORATION,
  a Delaware corporation
   
   
   
  By: /s/ Robert O. Hopkins
  Name: Robert O. Hopkins
  Title: SVP & CFO

 

 

 

 

 - 5 - 

 EX-101.SCH 4 admp-20200914.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 admp-20200914_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 admp-20200914_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 admp-8k_091420_htm.xml IDEA: XBRL DOCUMENT 0000887247 2020-09-14 2020-09-14 iso4217:USD shares iso4217:USD shares 0000887247 false 8-K 2020-09-14 ADAMIS PHARMACEUTICALS CORPORATION DE 0-26372 82-0429727 11682 El Camino Real Suite 300 San Diego CA 92130 (858) 997-2400 false false false false false Common Stock ADMP NASDAQ XML 8 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Cover
Sep. 14, 2020
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 14, 2020
Entity File Number 0-26372
Entity Registrant Name ADAMIS PHARMACEUTICALS CORPORATION
Entity Central Index Key 0000887247
Entity Tax Identification Number 82-0429727
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 11682 El Camino Real
Entity Address, Address Line Two Suite 300
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92130
City Area Code (858)
Local Phone Number 997-2400
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol ADMP
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://adamispharmaceuticals.com/role/Cover Cover Cover 1 false false All Reports Book All Reports admp-8k_091420.htm admp-20200914.xsd admp-20200914_lab.xml admp-20200914_pre.xml ex10-1.htm ex10-2.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "admp-8k_091420.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "admp-8k_091420.htm" ] }, "labelLink": { "local": [ "admp-20200914_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "admp-20200914_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "admp-20200914.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ADMP", "nsuri": "http://adamispharmaceuticals.com/20200914", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "admp-8k_091420.htm", "contextRef": "From2020-09-14to2020-09-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://adamispharmaceuticals.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "admp-8k_091420.htm", "contextRef": "From2020-09-14to2020-09-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-US": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://adamispharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 15 0001387131-20-008322-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001387131-20-008322-xbrl.zip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

@] !E>#$P+3(N:'1M4$L%!@ & 8 =0$ $Y< $! end